General Information of Drug (ID: DMRU4YV)

Drug Name
GSK-2018682 Drug Info
Synonyms PPI-4621; PPI-4667; PPI-4939; PPI-4955; PPI-4667-P; PPI-5955-P; S1P1 receptor agonists (immune disorder), GlaxoSmithKline
Indication
Disease Entry ICD 11 Status REF
Immune System disease 4A01-4B41 Phase 1 [1]
Cross-matching ID
PubChem CID
24988201
CAS Number
CAS 1034688-30-6
TTD Drug ID
DMRU4YV

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Siponimod DM2R86O Multiple sclerosis 8A40 Approved [3]
Fingolimod DM5JVAN Multiple sclerosis 8A40 Approved [4]
Ozanimod DMT6AM2 Multiple sclerosis 8A40 Approved [5]
Etrasimod DMT0A3Y Ulcerative colitis DD71 Approved [6]
Ponesimod DMEAOYJ Multiple sclerosis 8A40 Approved [7]
MT-1303 DMSE9TH Crohn disease DD70 Phase 2 [8]
ONO-4641 DMLUM3Y Rheumatoid arthritis FA20 Phase 2 [2]
KRP-203 DMOW9X2 Cutaneous lupus erythematosus EB5Z Phase 2 [2]
VTX-002 DMZ8Z5A Ulcerative colitis DD71 Phase 2 [9]
CBP-307 DM3TH6Y Ulcerative colitis DD71 Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Sphingosine-1-phosphate receptor 1 (S1PR1) TT9JZCK S1PR1_HUMAN Agonist [2]

References

1 ClinicalTrials.gov (NCT01387217) GSK2018682 FTIH in Healthy Volunteers. U.S. National Institutes of Health.
2 Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
4 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
8 Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis. CNS Drugs. 2015 Jul;29(7):565-75.
9 Clinical pipeline report, company report or official report of Ventyx Biosciences
10 Clinical pipeline report, company report or official report of Connect Biopharma